Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches.
about
Targeting neuropilin-1 in human leukemia and lymphomaRole of Microenvironment in Resistance to Therapy in AMLThe tandem PH domain-containing protein 2 (TAPP2) regulates chemokine-induced cytoskeletal reorganization and malignant B cell migrationCancer stem cells in basic science and in translational oncology: can we translate into clinical application?The microfluidic multitrap nanophysiometer for hematologic cancer cell characterization reveals temporal sensitivity of the calcein-AM efflux assay.Niche-based screening identifies small-molecule inhibitors of leukemia stem cellsExtracts from Curcuma zedoaria Inhibit Proliferation of Human Breast Cancer Cell MDA-MB-231 In Vitro.Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes.Bone marrow mesenchymal stem cells from patients with aplastic anemia maintain functional and immune properties and do not contribute to the pathogenesis of the disease.Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemiaTherapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.Platelets promote mitochondrial uncoupling and resistance to apoptosis in leukemia cells: a novel paradigm for the bone marrow microenvironmentOsteoblasts protect AML cells from SDF-1-induced apoptosis.Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance.Interleukin-18 produced by bone marrow-derived stromal cells supports T-cell acute leukaemia progressionThe CXCR4 antagonist AMD3465 regulates oncogenic signaling and invasiveness in vitro and prevents breast cancer growth and metastasis in vivoE- and p-selectins are essential for repopulation of chronic myelogenous and chronic eosinophilic leukemias in a scid mouse xenograft modelMesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts.Mimicking the functional hematopoietic stem cell niche in vitro: recapitulation of marrow physiology by hydrogel-based three-dimensional cultures of mesenchymal stromal cells.Three-dimensional co-culture of mesenchymal stromal cells and differentiated osteoblasts on human bio-derived bone scaffolds supports active multi-lineage hematopoiesis in vitro: Functional implication of the biomimetic HSC niche.The CCL2/CCR2 Axis Affects Transmigration and Proliferation but Not Resistance to Chemotherapy of Acute Myeloid Leukemia Cells.Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.Histone Deacetylase Inhibitors Target the Leukemic Microenvironment by Enhancing a Nherf1-Protein Phosphatase 1α-TAZ Signaling Pathway in OsteoblastsSynergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations.Cancer stem cells and chemoresistance: The smartest survives the raidUnderstanding and targeting cancer stem cells: therapeutic implications and challenges.Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling network.MiR-139-5p reverses CD44+/CD133+-associated multidrug resistance by downregulating NOTCH1 in colorectal carcinoma cells.Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance.Concise review: Nanoparticles and cellular carriers-allies in cancer imaging and cellular gene therapy?Chronic myeloid leukemia stem cells and developing therapies.The role of the microenvironment in tumor immune surveillance.Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.Physiology and pharmacology of plerixafor.Role of integrin alpha4 in drug resistance of leukemiaDPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia.The molecular mechanisms underlying the therapeutic resistance of cancer stem cells.Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia.Reciprocal Interactions of Leukemic Cells with Bone Marrow Stromal Cells Promote Enrichment of Leukemic Stem Cell Compartments in Response to Curcumin and Daunorubicin
P2860
Q24620098-73508C22-235B-450B-870C-510FA4682A27Q27027502-9C4EA1BD-4581-4E46-9F58-52EABA240CC2Q27312363-9F827B0B-8009-4136-9F4A-343EB636FD61Q28081844-1D1172BC-F1B5-4405-9EE9-B77AFA13AA32Q30579248-A7DF7C2B-03E8-416F-A828-0ED76DE98409Q33563509-295E76C2-1088-4F88-953C-5B4838C43E47Q33634352-6B6DD5F2-5D8B-42DC-832C-70A32F2D5627Q33795203-839DE1BA-F902-4A14-85FD-7CF803832906Q33828556-90D99D91-F481-4162-98E1-13D632740900Q33943277-CB8C94DD-0E58-4BDC-B43C-0D01DBA2BE04Q33952803-AE6396BD-ACD5-4AD2-9DB2-2816F0B0A7D1Q34115953-6C7F4B88-CB03-4883-9EE4-8EA031C4711BQ34164077-4A5AA4B8-2663-4FD0-A20C-0FD557E6FB1CQ34208986-EE5C09C9-2DCE-4257-BBA4-B750C0C31E59Q34372296-37261664-67F2-4335-AA79-C5A51E8AACF5Q34618835-57CC2AA3-9021-4646-ABCA-7302E6D2DFC3Q34906157-319BDF2F-DDC0-46E2-A1A9-71240C3B6E51Q35553350-420C7D3A-D944-486D-819B-EA296DC08E88Q35930551-3940C036-5C0E-4BBA-BB44-775D08FDEFE7Q36116127-98880938-3460-4D32-BBAF-B23439065F7EQ36237879-BE3E0784-1328-4D28-A32D-4DD1C173F2E0Q36286881-B0AE2846-CAEA-4BB0-927D-ABE6D1F6E992Q36444091-74297D88-9D5E-446F-A756-6DD5C52DA486Q36544358-74506EBE-F618-497E-9476-9B94E02286D5Q36693252-109BD160-4554-427B-BD02-8D2D21A4DA0BQ36730432-5BCA1862-2605-4E69-B665-937074D91906Q36907405-F8CB6914-B737-4DE6-AB26-CB2DBCF074EFQ37190250-6309E143-670E-49AC-9CF8-3BE7BA394E58Q37688905-426F19F0-AEE6-4F11-9490-0302865BA823Q37723478-6D2CE6BF-3363-4769-9741-AC1E2ABD41A7Q37772453-0F27F5BE-56BD-4D17-B409-B39AE48634F6Q37836936-B57EEEA2-B49B-4DDA-838C-28BB5E012619Q37848669-D17B9C93-91BD-485E-B89D-6624D8F92949Q38097334-F39EA76B-6DCE-419F-8A7A-7B65E446FE99Q38157897-DA05C065-0E34-4F35-A0E6-4F42AC13107DQ38218126-87D61001-BF4B-4081-80EA-2C9E237661E0Q38265115-E921B950-DE2D-42A4-BAFF-01D214639C90Q38287226-069348C2-A246-4B17-8C9B-3C6E2B2B4762Q38673618-5D46BEE2-27B6-4EAF-8ECD-0B6809CC12BEQ38706127-F2E9537D-D1C0-416B-8EEA-E191EF3723DF
P2860
Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapeutic targeting of micro ...... ia: mechanisms and approaches.
@en
Therapeutic targeting of micro ...... ia: mechanisms and approaches.
@nl
type
label
Therapeutic targeting of micro ...... ia: mechanisms and approaches.
@en
Therapeutic targeting of micro ...... ia: mechanisms and approaches.
@nl
prefLabel
Therapeutic targeting of micro ...... ia: mechanisms and approaches.
@en
Therapeutic targeting of micro ...... ia: mechanisms and approaches.
@nl
P2860
P1476
Therapeutic targeting of micro ...... ia: mechanisms and approaches.
@en
P2093
Zhihong Zeng
P2860
P304
P356
10.1016/J.DRUP.2009.06.001
P577
2009-07-25T00:00:00Z